Document is current
Any future updates will be listed below
-
Authors
Hu, Xingsheng
Zheng, Xin
Yang, Sheng
Wang, Lin
Hao, Xuezhi
Cui, Xinge
Ding, Lieming
Mao, Li
Hu, Pei
Shi, Yuankai http://orcid.org/0000-0002-8450-7583
-
Funding
Funding for this research was provided by:
China National Major Project for New Drug Innovation (2017ZX09304015)
CAMS Innovation Fund for Medical Sciences (2016-I2M-1-001)
- License Information
-
More Information
Article History
Received: 26 August 2019
Accepted: 4 December 2019
First Online: 16 January 2020
Ethics approval and consent to participate
: This study was performed in accordance with the Declaration of Helsinki and the principles of Good Clinical Practice. The protocol was approved by the ethics review board of Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital at each site and all patients provided written informed consent before study entry.
: All patients provided written informed consent for publication.
: Li Mao and Lieming Ding is an employee and a stock owner of Betta Pharmaceuticals. All the remaining authors have declared no conflicts of interest.
